News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Argos Therapeutics, Inc. Receives FDA Approval of Special Protocol Assessment for AGS-003 Phase 3 Trial



7/2/2012 9:31:10 AM

DURHAM, N.C., July 2, 2012 (GLOBE NEWSWIRE) -- Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelis™ technology platform, today announced the U.S. Food & Drug Administration (FDA) has approved the Company's revised Special Protocol Assessment (SPA) for its Phase 3 clinical study of AGS-003 for the treatment of metastatic renal cell carcinoma (mRCC). The Autologous Dendritic Cell Immunotherapy (AGS-003) Plus Standard Treatment of Advanced Renal Cell Carcinoma (ADAPT) study has initiated and is expected to begin dosing patients in the second half of 2012, with a primary clinical endpoint of overall survival.

Read at GlobeNewswire


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES